ECKERT & ZIEGLER SE |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.88 EUR | +1.96% |
|
-0.43% | +10.93% |
| 15/05 | ECKERT & ZIEGLER : Hauck & Aufhauser reiterates its Buy rating | ZD |
| 14/05 | Eckert & Ziegler SE Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 271M 294M 24.54B | Sales 2025 * | 296M 322M 26.84B | Capitalization | 952M 1.03B 86.15B |
|---|---|---|---|---|---|
| Net income 2024 * | 34M 36.87M 3.08B | Net income 2025 * | 36M 39.04M 3.26B | EV / Sales 2024 * | 3.35 x |
| Net cash position 2024 * | 43.4M 47.07M 3.93B | Net cash position 2025 * | 42.6M 46.2M 3.86B | EV / Sales 2025 * | 3.07 x |
| P/E ratio 2024 * |
27.5
x | P/E ratio 2025 * |
25.8
x | Employees | 1,072 |
| Yield 2024 * |
1.1% | Yield 2025 * |
1.1% | Free-Float | 67.02% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eckert & Ziegler SE
More recommendations
More press releases
More news
| 1 day | +1.96% | ||
| 1 week | -0.43% | ||
| 1 month | +22.61% | ||
| 3 months | +8.31% | ||
| 6 months | +22.35% | ||
| Current year | +10.93% |
1 week
44.24
45.88
1 month
37.0446.76
Current year
33.0646.76
1 year
29.2646.76
3 years
29.26137.60
5 years
24.50137.60
10 years
24.50137.60
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 01/17/01 | |
Andreas Eckert
FOU | Founder | 55 | 01/97/01 |
Karolin Riehle
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Edgar Löffler
BRD | Director/Board Member | 71 | 01/19/01 |
Andreas Eckert
FOU | Founder | 55 | 01/97/01 |
Frank Perschmann
BRD | Director/Board Member | 71 | 29/19/29 |
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 45.88 | +1.96% |
| 30/24/30 | 45 | +1.72% |
| 29/24/29 | 44.24 | -1.16% |
| 28/24/28 | 44.76 | -2.23% |
| 27/24/27 | 45.78 | -0.65% |
End-of-day quote Borsa Italiana, May 31, 2024
More quotes
Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
Sector
Office Equipment
Calendar
18/06/2024
- Kepler Chevreux SMID Conference
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
45.66
EUR
Average target price
62.5
EUR
Spread / Average Target
+36.88%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.20% | 7.63B | |
| -6.99% | 4.53B | |
| -4.77% | 2.98B | |
| +8.82% | 2.19B | |
| -30.15% | 1.07B | |
| +4.09% | 905M | |
| -47.58% | 829M | |
| -19.25% | 719M | |
| -29.15% | 696M |
- Stock Market
- Equities
- EUZ Stock
- 4EUZ Stock
